Process for treating lameness with an osseous, articular or osteoarticular component in human or veterinary medicine, comprising the administration of a bisphosphonic acid derivative

Abstract

The invention relates to a process for treating lameness with an osseous, articular or osteoarticular component, comprising the administration, to a human or to an animal not suffering from arthritis or from fractures, of an effective amount of a bisphosphonic acid derivative of formula: in which: R 1 represents a hydrogen atom, a halogen atom, a hydroxyl, an amino, a mono(C 1 -C 4 )alkylamino or a di(C 1 -C 4 )alkylamino; R 2 represents a halogen atom, a linear alkyl comprising from 1 to 5 carbon atoms which is unsubstituted or substituted with a group chosen from a chlorine atom, a hydroxyl, an amino, a mono(C 1 -C 4 )alkylamino or a di(C 1 -C 4 )alkylamino; a (C 3 -C 7 )cycloalkylamino, or R 2 represents a phenoxy, a phenyl, a thiol, a phenylthio, a chlorophenylthio, a pyridyl, a pyridylmethyl, a 1-pyridyl-1-hydroxymethyl, an imidazolylmethyl or a 4-thiomorpholinyl, of one of its pharmaceutically acceptable salts or of one of its hydrates.

1 - 11 . (canceled)  
   
   
       12 . Process for treating lameness that appears during osteoarthrosis comprising the administration, to a human or to an animal not suffering from arthritis or from fractures, of an effective amount of a bisphosphonic acid derivative selected from the group consisting of: 
 1-hydroxyethylidenebisphosphonic acid and its sodium salts;    2-pyrid-2-ylethylidenebisphosphonic acid and its sodium salts;    phenoxymethylenebisphosphonic acid and its salts;    thiomorpholinomethylenebisphosphonic acid and its salts;    4-chlorophenylthiomethylenebisphosphonic acid and its salts;    1-hydroxy-2-(3-pyridyl)ethylidenebisphosphonic acid and its sodium salts;    1-hydroxy-2-(2-imidazolyl)ethyl-1,1-bisphosphonic acid and its salts; and    2-hydroxyethylidene-2-(3-pyridyl)-1,1-bisphosphonic acid and its sodium salts.    
   
   
       13 . Process according to  claim 12 , for treating an animal belonging to the equidae family.  
   
   
       14 . Process according to  claim 12 , for treating a horse.  
   
   
       15 . Process according to  claim 12 , comprising the administration of 0.001 mg/kg to 100 mg/kg of body weight of the bisphosphonic acid derivative.  
   
   
       16 . Process according to  claim 12 , for treating limps in horses, comprising the intravenous administration of 0.01 mg/kg/week to 1 mg/kg/week of tiludronic acid or one of its pharmaceutically acceptable salts.  
   
   
       17 . Process according to  claim 12 , comprising the oral administration of the bisphosphonic acid derivative.  
   
   
       18 . Process according to  claim 12 , comprising the parenteral administration of the isphosphonic acid derivative.  
   
   
       19 . Process according to  claim 12 , comprising the administration of the bisphosphonic acid derivative in the form of an implant.  
   
   
       20 . Process according to  claim 12 , in which the bisphosphonic acid derivative is 4-chlorophenylthiomethylenebisphosphonic acid.